Progression of bone loss on oral formulations Copyright 2016 F A Davis Company

Progression of bone loss on oral formulations

This preview shows page 13 - 17 out of 29 pages.

Progression of bone loss on oral formulations Copyright © 2016 F. A. Davis Company
Image of page 13
____ 18. What is the established frequency of repeating DEXA imaging after stating bisphosphonates? 1. Every 2 years 2. Every 5 years 3. There is no evidence-based time line for monitoring after the first 2 years 4. There need to be annual exams ____ 19. What is the duration of SERM use for menopausal issues? 1. It matches the 5 years for estrogen products 2. The bone health impact allows long-term use 3. The increased risk of breast cancer encourages tapering as soon as possible 4. The abnormal lipid profile contributes to an early termination as soon as hot flashes no longer occur ____ 20. Why are SERMS generally not ordered for women early into menopause? 1. The rapid onset of severe hot flashes can be unbearable. 2. The bone remodeling effect results in osteoporosis. 3. They tend to induce intermittent spotting. 4. They create more risk with breast cancer than they are worth. Copyright © 2016 F. A. Davis Company
Image of page 14
Chapter 38. Hormone Replacement Therapy and Osteoporosis Answer Section MULTIPLE CHOICE 1. ANS: 4 PTS: 1 2. ANS: 2 PTS: 1 3. ANS: 3 PTS: 1 4. ANS: 3 PTS: 1 5. ANS: 1 PTS: 1 6. ANS: 4 PTS: 1 7. ANS: 3 PTS: 1 8. ANS: 2 PTS: 1 9. ANS: 2 PTS: 1 10. ANS: 4 PTS: 1 11. ANS: 3 PTS: 1 12. ANS: 2 PTS: 1 13. ANS: 1 PTS: 1 14. ANS: 1 PTS: 1 15. ANS: 3 PTS: 1 16. ANS: 2 PTS: 1 17. ANS: 3 PTS: 1 18. ANS: 3 PTS: 1 19. ANS: 2 PTS: 1 20. ANS: 1 PTS: 1 Chapter 44. Sexually Transmitted Infections and Vaginitis Multiple Choice Identify the choice that best completes the statement or answers the question. ____ 1. The goals of treatment when prescribing for sexually transmitted infections include: 1. Treatment of infection 2. Prevention of disease spread 3. Prevention of long-term sequelae from the infection 4. All of the above ____ 2. The drug of choice for treatment of primary or secondary syphilis is: 1. Ceftriaxone IM 2. Benzathine penicillin G IM 3. Oral azithromycin Copyright © 2016 F. A. Davis Company
Image of page 15
4. Oral ciprofloxacin ____ 3. The drug of choice for treatment of early latent or tertiary syphilis is: 1. Ceftriaxone IM 2. Benzathine penicillin G IM 3. Oral azithromycin 4. Oral ciprofloxacin ____ 4. Demione is a 24-year-old patient who is 32 weeks pregnant and has tested positive for syphilis. The best treatment for her would be: 1. IM ceftriaxone 2. IM benzathine penicillin G 3. Oral azithromycin 4. Any of the above ____ 5. Treatment for suspected gonorrhea is: 1. Ceftriaxone 250 mg IM x 1 2. Ceftriaxone 2 grams IM x 1 3. Ciprofloxacin 500 mg PO x 1 4. Doxycycline 100 mg bid x 7 days ____ 6. When treating suspected gonorrhea in a nonpregnant patient, the patient should be concurrently treated for chlamydia with: 1. Azithromycin 1 gram PO x 1 2. Amoxicillin 500 mg PO x 1 3. Ciprofloxacin 500 mg PO x 1 4. Penicillin G 2.4 million units IM x 1 ____ 7. Ongoing monitoring is essential after treating for gonorrhea. The patient should be rescreened for gonorrhea and chlamydia in: 1. 4 weeks 2. 3 to 6 weeks 3. 3 to 6 months 4. 1 year ____ 8.
Image of page 16
Image of page 17

You've reached the end of your free preview.

Want to read all 29 pages?

  • Fall '18
  • F. A. Davis Company, estrogen, Combined oral contraceptive pill

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture